Evidence map›Paper›PMID 32221808›Full record

SynthesisJournal of thrombosis and thrombolysis2020

Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.

Qi Kong, Xin Ma, Xiaoxi Zhao, Fei Chen, Chengbei Hou

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Clinical perspectives on ischemic stroke.Experimental neurology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Qi KongDepartment of Neurology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China.
Xin MaDepartment of Neurology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China. maxin118@hotmail.com.
Xiaoxi ZhaoDepartment of Neurology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China.
Fei ChenDepartment of Neurology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China.
Chengbei HouEvidence-Based Medicine Center, Xuanwu Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNNational Clinical Research Center for Digestive Diseases · CN

Funding

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support ZYLX201706Natural Science Foundation of Beijing Municipality 7172093
6 · The paper itself

Abstract

Coronary artery disease (CAD) patients had a higher risk of first-ever stroke than general population even when they were on antiplatelet treatment. It was unknown whether more potent antiplatelet inhibitor ticagrelor which also provided adenosine-mediated protection would improve the primary stroke prevention for CAD. PubMed, Embase, Web of Science and CERNTRAL were searched for randomized clinical trials (RCTs) comparing efficacy and safety outcomes of over 30-day use of ticagrelor versus other antiplatelet drugs or placebo in patients with acute or chronic coronary syndrome. RCTs involving patients with any stroke history were excluded. Based on 5 RCTs with 45,843 patients, ticagrelor-involving regimens significantly reduced first-ever strokes (risk ratio [RR] 0.81; 95% confidential interval [CI] 0.71-0.94; I

Indexed as

Coronary Artery DiseaseStrokeHumansPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicTicagrelorTreatment OutcomePlatelet Aggregation InhibitorsTicagrelorAntiplateletCoronary artery diseaseMeta-analysisPrimary stroke preventionTicagrelor

Identifiers

PMID32221808
OpenAlexW3013592673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.